The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Detection of sarcomatoid renal cell carcinoma using plasma cell-free DNA methylation.
 
Karl Semaan
No Relationships to Disclose
 
Talal El Zarif
No Relationships to Disclose
 
Ji-Heui Seo
No Relationships to Disclose
 
Marc Eid
No Relationships to Disclose
 
John Canniff
No Relationships to Disclose
 
Brad Fortunato
No Relationships to Disclose
 
Hunter Savignano
No Relationships to Disclose
 
Matthew P. Davidsohn
No Relationships to Disclose
 
Gitanjali Lakshminarayanan
No Relationships to Disclose
 
Eddy Saad
No Relationships to Disclose
 
Renee Maria Saliby
No Relationships to Disclose
 
Ziad Bakouny
Honoraria - UpToDate
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Sayed Matar
No Relationships to Disclose
 
Pier VItale Nuzzo
No Relationships to Disclose
 
Jacob E Berchuck
Employment - Cityblock Health (I)
Stock and Other Ownership Interests - Cityblock Health (I); Genome Medical; Musculo; Oncotect; Precede Bio; TracerDx
Honoraria - Guardant Health; UroToday
Consulting or Advisory Role - Genome Medical; Guardant Health; JucaBio; JucaBio; Musculo; Oncotect; Precede Bio; TracerDx
Speakers' Bureau - Guardant Health
Patents, Royalties, Other Intellectual Property - Institutional patent filed on methods for detecting prostate cancer resistance using cell-free DNA
Travel, Accommodations, Expenses - Guardant Health
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; crispr therapeutics; Merck
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Receives royalties from Biogenex
Other Relationship - AACR; NCI
 
David A. Braun
Stock and Other Ownership Interests - CurIOS Therapeutics; Elephas Bio; Fortress Biotech (subsidiary)
Consulting or Advisory Role - Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; CurIOS Therapeutics; Dedham Group; Defined Health; DLA Piper; Elephas Bio; Exelixis; Insight Strategy; Merck; Octane Co.; Schlesinger Associates; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Matthew Freedman
Stock and Other Ownership Interests - Precede Bio
Consulting or Advisory Role - Precede Bio
Patents, Royalties, Other Intellectual Property - A pending patent has been filed for detecting neuroendocrine prostate cancer using DNA methylation
 
Sylvan Baca
Stock and Other Ownership Interests - Precede Bio
Consulting or Advisory Role - Precede Bio
Patents, Royalties, Other Intellectual Property - Precede Bio
 
Toni K. Choueiri
Stock and Other Ownership Interests - Curesponse; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics
Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel